Standard Versus Reduced‐Doses of Post‐Transplant Cyclophosphamide in HLA Matched (10/10) Peripheral Blood Stem Cell Transplantation
European Journal of Haematology · 2025-10 · 115 (4) · 413-422
DOI: 10.1111/ejh.70010 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 23.07.2025. Verfasst von Sara Redondo und 17 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Hospital de la Sant Creu i Sant Pau. IR-Sant Pau and José Carreras Leukemia Research Institutes, Universitat Autónoma de Barce…. Hauptthemen laut MEDLINE: Cyclophosphamide, Peripheral Blood Stem Cell Transplantation, Immunosuppressive Agents, HLA Antigens. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Objective
This retrospective, single‐center study aims to compare the efficacy and safety of a reduced dose of post‐transplantation cyclophosphamide (PTCy) (60 mg/kg total dose) versus the standard dose (100 mg/kg total dose), both combined with tacrolimus, in adult patients undergoing allogeneic hematopoietic stem cell transplantation from HLA‐matched related or unrelated donors.
Methods
We report clinical outcomes of 59 consecutive patients who received standard doses of PTCy and 48 with the new reduced dose.
Results
Neutrophil and platelet recovery occurred later in the standard‐dose group ( p < 0.01). The incidence of febrile neutropenia was higher in the standard‐dose group ( p < 0.01). No significant differences were found in the incidence of acute cardiac events, early bacteremia, CMV reactivation within the first 100 days post‐HSCT, or the development of hemorrhagic cystitis. There were no significant differences in the incidence of grade II–IV and III–IV acute GvHD, moderate‐to‐severe chronic GvHD, or in 20‐month overall survival and progression‐free survival ( p > 0 . 05). Non‐relapse mortality at 100 days and at 1 year was comparable between groups, as was 1‐year GVHD‐free/relapse‐free and immunosuppression‐free survival ( p > 0 . 05).
Conclusions
Reduced doses of CyPT combined with a single immunosuppressive agent are emerging as a safe and effective alternative for adult patients undergoing allo‐HSCT from HLA‐matched donors. Our findings support that this approach preserves key clinical outcomes while potentially reducing acute hematological and infectious toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Department, Hospital de la Sant Creu i Sant Pau. IR-Sant Pau and José Carreras Leukemia Research Institutes, Universitat Autónoma de Barcelona, Bellaterra, Spain.
- Pharmacy Department, Hospital de la Sant Creu i Sant Pau. IR-Sant Pau, Barcelona, Spain.
ORCID-Profile: Sara Redondo, Jorge Sierra
Zitieren
APA
Redondo, S., García-Cadenas, I., Esquirol, A., Iranzo, E., Arguello-Tomas, M., Saavedra, S., Oñate, G., Caballero, A. C., Garrido, A., López, J., Muntañola, A., Paviglianiti, A., Portos, J. M., Moreno-Martinez, M. E., Riba, M., Sierra, J., Briones, J., & Martino, R. (2025). Standard Versus Reduced‐Doses of Post‐Transplant Cyclophosphamide in HLA Matched (10/10) Peripheral Blood Stem Cell Transplantation. European Journal of Haematology, 115(4), 413-422. https://doi.org/10.1111/ejh.70010
Vancouver
Redondo S, García-Cadenas I, Esquirol A, Iranzo E, Arguello-Tomas M, Saavedra S, et al. Standard Versus Reduced‐Doses of Post‐Transplant Cyclophosphamide in HLA Matched (10/10) Peripheral Blood Stem Cell Transplantation. European Journal of Haematology. 2025;115(4):413-422. doi:10.1111/ejh.70010
BibTeX
@article{Redondo2025,
author = {Redondo, Sara and García-Cadenas, Irene and Esquirol, Albert and Iranzo, Eva and Arguello-Tomas, Miguel and Saavedra, Silvana and Oñate, Guadalupe and Caballero, Ana-Carolina and Garrido, Ana and López, Jordi and Muntañola, Ana and Paviglianiti, Annalisa and Portos, Jose Manuel and Moreno-Martinez, Maria Estela and Riba, Mireia and Sierra, Jorge and Briones, Javier and Martino, Rodrigo},
title = {Standard Versus Reduced‐Doses of Post‐Transplant Cyclophosphamide in HLA Matched (10/10) Peripheral Blood Stem Cell Transplantation},
journal = {European Journal of Haematology},
year = {2025},
volume = {115},
number = {4},
pages = {413--422},
doi = {10.1111/ejh.70010}
}
EUVIMED